Johansen and colleagues (1999) reported that ipamorelin administration was associated with dose-dependent longitudinal bone growth in rats over a 15-day study, an effect the authors attributed to downstream GH-mediated action rather than a direct skeletal mechanism [4]
Bone , 24 3, 195-202
Notably, this study included broad range of GLP-1 drugs, including much older GLP-1s that have far lower anti-obesity, anti-craving, and anti-addictive effects: abiglutide (Eperzan, Tanzeum), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin, Lyxumia), semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro) Its possible that the associations that were found would be even stronger if the study had looked exclusively at semaglutide and tirzepatide, which are the current best-in-class options for weight loss
I think this is maybe what some U.S